The use of thermal ablation in diverse cervical cancer "screen-and-treat" service platforms in Zambia.

dc.contributor.affiliationZambia Ministry of Health, Cancer Control, Lusaka, Zambia.
dc.contributor.affiliationDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.
dc.contributor.affiliationInternational Agency for Research on Cancer, WHO Screening Group, Early Detection and Prevention Section, Lyon, France.
dc.contributor.affiliationCenter for Infectious Disease Research in Zambia, Cervical Cancer Prevention Program, Lusaka, Zambia.
dc.contributor.affiliationDepartment of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
dc.contributor.affiliationDepartment of Obstetrics and Gynecology, Women and Newborn Hospital, Lusaka, Zambia.
dc.contributor.affiliationCIDRZ
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.contributor.authorMwanahamuntu M
dc.contributor.authorKapambwe S
dc.contributor.authorPinder LF
dc.contributor.authorMatambo J
dc.contributor.authorChirwa S
dc.contributor.authorChisele S
dc.contributor.authorBasu P
dc.contributor.authorPrendiville W
dc.contributor.authorSankaranarayanan R
dc.contributor.authorParham GP
dc.date.accessioned2025-05-23T11:40:58Z
dc.date.issued2022-Apr
dc.description.abstractOBJECTIVE: Thermal ablation (TA) was implemented in public sector cervical cancer prevention services in Zambia in 2012. Initially introduced as a treatment modality in primary healthcare clinics, it was later included in mobile outreach campaigns and clinical research trials. We report the feasibility, acceptability, safety, and provider uptake of TA in diverse clinical contexts. METHODS: Screening services based on visual inspection with acetic acid were offered by trained nurses to non-pregnant women aged 25-59 years. Women with a type 1 transformation zone (TZ) were treated with same-visit TA. Those with a type 2 or 3 TZ, or suspicious for cancer, were managed with same-visit electrosurgical excision or punch biopsy, respectively. A provider survey was conducted. RESULTS: Between 2012 and 2020, 2123 women were treated with TA: primary healthcare clinics, n = 746; mobile outreach clinics, n = 1127; research clinics, n = 250. Of the 996 women treated in primary healthcare and research clinics, 359 (48%) were HIV positive. Mild cramping during treatment was the most common adverse effect. No treatment interruptions occurred. No major complications were reported in the early (6 weeks) follow-up period. Providers expressed an overwhelming preference for TA over cryotherapy. CONCLUSION: TA was feasible, safe, and acceptable in diverse clinical contexts. It was the preferred ablation method of providers when compared with cryotherapy.
dc.identifier.doi10.1002/ijgo.13808
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/10359
dc.sourceInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
dc.titleThe use of thermal ablation in diverse cervical cancer "screen-and-treat" service platforms in Zambia.

Files

Collections